# Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port

> **NCT00790699** · NA · TERMINATED · sponsor: **Texas Diabetes & Endocrinology, P.A.** · enrollment: 31 (actual)

## Conditions studied

- Type 1 Diabetes
- Type 2 Diabetes

## Interventions

- **DEVICE:** I-PORT
- **OTHER:** standard injections

## Key facts

- **NCT ID:** NCT00790699
- **Lead sponsor:** Texas Diabetes & Endocrinology, P.A.
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-08
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Lack of patient population
- **Last updated:** 2020-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00790699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00790699, "Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00790699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*